These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 9385505)

  • 1. The clinical significance of neurohormonal activation.
    Pool PE
    Clin Ther; 1997; 19 Suppl A():53-73. PubMed ID: 9385505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurohormonal activation in the treatment of congestive heart failure: basis for new treatments?
    Pool PE
    Cardiology; 1998 Jul; 90(1):1-7. PubMed ID: 9693163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure.
    Packer M
    Circulation; 1989 Dec; 80(6 Suppl):IV59-67. PubMed ID: 2688986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the role of calcium channel antagonists in heart failure due to systolic dysfunction.
    Mahé I; Chassany O; Grenard AS; Caulin C; Bergmann JF
    Am J Cardiovasc Drugs; 2003; 3(1):33-41. PubMed ID: 14727944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of neurohormonal activation in chronic heart failure and postmyocardial infarction.
    Sigurdsson A; Swedberg K
    Am Heart J; 1996 Jul; 132(1 Pt 2 Su):229-34. PubMed ID: 8677861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving role of calcium channel blockers in heart failure.
    Pieper JA
    Pharmacotherapy; 1996; 16(2 Pt 2):43S-49S. PubMed ID: 8668605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure.
    Coats AJ; Adamopoulos S
    Cardiovasc Drugs Ther; 1994 Oct; 8(5):685-92. PubMed ID: 7873465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neuroendocrine and sympathetic nervous system in congestive heart failure.
    Ferrari R; Ceconi C; Curello S; Visioli O
    Eur Heart J; 1998 Jun; 19 Suppl F():F45-51. PubMed ID: 9651735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease.
    Packer M
    Eur Heart J; 1996 Apr; 17 Suppl B():21-3. PubMed ID: 8733067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium channel blockers in heart failure.
    Elkayam U; Shotan A; Mehra A; Ostrzega E
    J Am Coll Cardiol; 1993 Oct; 22(4 Suppl A):139A-144A. PubMed ID: 8376684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure.
    Cavero PG; De Marco T; Kwasman M; Lau D; Liu M; Chatterjee K
    J Am Coll Cardiol; 1992 Dec; 20(7):1542-8. PubMed ID: 1452928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.
    Packer M
    J Am Coll Cardiol; 1992 Jul; 20(1):248-54. PubMed ID: 1351488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurohormonal activation in heart failure with reduced ejection fraction.
    Hartupee J; Mann DL
    Nat Rev Cardiol; 2017 Jan; 14(1):30-38. PubMed ID: 27708278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure.
    Packer M; Lee WH; Kessler PD; Gottlieb SS; Bernstein JL; Kukin ML
    Circulation; 1987 May; 75(5 Pt 2):IV80-92. PubMed ID: 2882867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels.
    Nootens M; Kaufmann E; Rector T; Toher C; Judd D; Francis GS; Rich S
    J Am Coll Cardiol; 1995 Dec; 26(7):1581-5. PubMed ID: 7594089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hormonal theory of heart failure with altered systolic function].
    Arnoult F; Phan G; Detaint D; Caligiuri G; Aumont MC; Mercadier JJ; Jondeau G
    Rev Med Interne; 2010 Oct; 31(10):721-5. PubMed ID: 20864226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.
    Benedict CR; Shelton B; Johnstone DE; Francis G; Greenberg B; Konstam M; Probstfield JL; Yusuf S
    Circulation; 1996 Aug; 94(4):690-7. PubMed ID: 8772689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experts consensus on the management of the right heart function in critically ill patients].
    Wang XT; Liu DW; Zhang HM; Long Y; Guan XD; Qiu HB; Yu KJ; Yan J; Zhao H; Tang YQ; Ding X; Ma XC; Du W; Kang Y; Tang B; Ai YH; He HW; Chen DC; Chen H; Chai WZ; Zhou X; Cui N; Wang H; Rui X; Hu ZJ; Li JG; Xu Y; Yang Y; Ouyan B; Lin HY; Li YM; Wan XY; Yang RL; Qin YZ; Chao YG; Xie ZY; Sun RH; He ZY; Wang DF; Huang QQ; Jiang DP; Cao XY; Yu RG; Wang X; Chen XK; Wu JF; Zhang LN; Yin MG; Liu LX; Li SW; Chen ZJ; Luo Z;
    Zhonghua Nei Ke Za Zhi; 2017 Dec; 56(12):962-973. PubMed ID: 29202543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathophysiology of heart failure.
    Kemp CD; Conte JV
    Cardiovasc Pathol; 2012; 21(5):365-71. PubMed ID: 22227365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.